Zymeworks Inc. (ZYME)
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
Zymeworks (NASDAQ: ZYME) used a presentation at the Bloom Burton conference to outline how the company is repositioning itself around its first approved product and a growing stream of royalty and milestone revenue, while continuing to invest in internal research and development across antibody-drug conjugates (ADCs) and multispecific antibodies. The speaker, who noted it was the
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Zymeworks Inc. (NASDAQ: ZYME - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have assigned a buy recommendation and
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside
Zymeworks Inc. (ZYME) reported weak Q4 results, highlighting the volatility of its milestone-driven revenue model and underscoring execution risk ahead of commercialization. Despite top-line misses, ZYME improved FY25 profitability, narrowed net loss by 34%, and maintained strong liquidity with $270.6 million in cash and equivalents. The $250 million royalty-backed financing with Royalty Pharma extends ZYME's cash runway beyond 2028, reducing dilution risk but increasing dependence on Ziihera's commercial success.
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.31 per share a year ago.
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth
Zymeworks delivered strong Phase 3 HERIZON-GEA-01 results for Ziihera, achieving over two years median overall survival in HER2-positive GEA. ZYME stands to receive up to $440 million in milestone payments upon regulatory approvals, dwarfing its recent $27.6 million quarterly revenue. Ziihera's efficacy was consistent across PD-L1 subgroups, with manageable safety, positioning it as a potential new first-line standard for HER2-positive GEA.
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA
Zymeworks is gaining momentum as Ziihera shows strong Phase III data in HER2+ gastroesophageal adenocarcinoma, supporting growth and de-risking the investment. ZYME's royalty-based business model with partners like Jazz and BeOne enables pipeline focus while targeting blockbuster potential, with peak sales estimates exceeding $2B for Ziihera. Risks remain, including regulatory uncertainties and competition from ENHERTU, but ZYME's solid cash position and clinical progress support a 3/5 conviction rating.
Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript
Zymeworks Inc. ( ZYME ) Shareholder/Analyst Call November 18, 2025 8:30 AM EST Company Participants Shrinal Inamdar - Director of Investor Relations Kenneth Galbraith - Chairman of the Board, CEO & President Conference Call Participants Seung Won Paik - LifeSci Capital, LLC, Research Division Andrew Berens - Leerink Partners LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Joohwan Kim Jonathan Miller - Evercore ISI Institutional Equities, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Yaron Werber - TD Cowen, Research Division Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Presentation Operator Thank you for standing by, and welcome to Zymeworks Strategy Update Conference Call and Webcast.
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in combination with Tevimbra and chemotherapy outperformed trastuzumab plus chemotherapy, and the triple combination achieved statistically significant overall survival benefit. The GEA indication represents a $2 billion+ a year opportunity for JAZZ and a $300 million opportunity for BeOne, and ZYME stands to benefit by receiving royalties from both partners.
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.
